Thymosin alpha-1 is an immune-modulating peptide with a genuine clinical
footprint in several countries — a stronger evidence position than most
compounds in this library. This monograph covers the pharmacology and that
record.
Chemical identity & structure.
Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide with an acetylated
N-terminus. It corresponds to a fragment originally isolated from thymosin
fraction 5, a thymus-gland preparation. The synthetic pharmaceutical form is
known as thymalfasin. It is a well-defined peptide of moderate length.
Mechanism of action.
Thymosin alpha-1 is an immunomodulator rather than a simple immune stimulant. It
is reported to influence the maturation and function of T cells, to affect
dendritic-cell activity, and to modulate signaling through Toll-like receptors.
The net effect described in the literature is a "tuning" of immune responses —
which is why it has been investigated both where immune function is
underactive and as an adjuvant.
Key research findings.
Thymosin alpha-1 has been studied as an adjunct in chronic viral hepatitis (B
and C), as a vaccine adjuvant, and in immune support for certain patient
populations. The literature includes human clinical research, and the compound
has been used clinically in a number of countries for years.
The research / citation base.
Thymalfasin is approved and marketed in several countries (it is not FDA-
approved in the United States) for indications including chronic hepatitis. It
therefore has a real human clinical literature behind its approved uses. Claims
beyond those indications are less well supported.
In the prospective, multicenter, randomized, open-label study by Kim et al. (2012) in HBeAg-positive chronic hepatitis B patients, the combination group (26 patients) received 180 μg of peginterferon α-2a weekly for 48 weeks and 1.6 mg of thymosin α-1 twice a week for the first 12 weeks, versus peginterferon α-2a alone (25 patients); the study authors concluded the short-term addition of thymosin α-1 was not superior on antiviral efficacy (PubMed).
Quality & sourcing notes.
A 28-mer with an acetylated terminus should be confirmed on a batch-specific COA
by mass spectrometry (the acetylation affects the expected mass) and HPLC
purity. Verify the COA describes thymosin alpha-1 specifically and not a
different thymic peptide.
*Research-use note: Educational summary of published research. Thymosin alpha-1
is described here for research context; it is not FDA-approved, and nothing here
is medical advice.*
